187
Views
2
CrossRef citations to date
0
Altmetric
Article

STAT1 participates in the induction of substance P expression in airway epithelial cells by respiratory syncytial virus

ORCID Icon, , , , , , & show all
Pages 78-86 | Received 24 Jul 2020, Accepted 09 Nov 2020, Published online: 26 Nov 2020

References

  • Nelson DA, Bost KL. Non-neuronal mammalian tachykinin expression. Front Biosci. 2004;9:2166–2176. doi:10.2741/1372.
  • Bracci-Laudiero L, Aloe L, Caroleo MC, et al. Endogenous NGF regulates CGRP expression in human monocytes, and affects HLA-DR and CD86 expression and IL-10 production. Blood. 2005;106(10):3507–3514. doi:10.1182/blood-2004-10-4055.
  • Stewart JP, Kipar A, Cox H, Payne C, Vasiliou S, Quinn JP. Induction of tachykinin production in airway epithelia in response to viral infection. PLoS One. 2008;3(3):e1673 doi:10.1371/journal.pone.0001673.
  • Dakhama A, Park J, Taube C, et al. Alteration of airway neuropeptide expression and development of airway hyperresponsiveness following respiratory syncytial virus infection. Am J Physiol Lung Cell Mol Physiol. 2005;288(4):L761–L770. doi:10.1152/ajplung.00143.2004.
  • Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev. 2014;94(1):265–301. doi:10.1152/physrev.00031.2013.
  • Hökfelt T, Pernow B, Wahren J. Substance P: a pioneer amongst neuropeptides. J Intern Med. 2001;249(1):27–40. doi:10.1046/j.0954-6820.2000.00773.x.
  • Devane CL. Substance P: a new era, a new role. Pharmacotherapy. 2001;21(9):1061–1069. doi:10.1592/phco.21.13.1061.34612.
  • Yang L, Di G, Qi X, et al. Substance P promotes diabetic corneal epithelial wound healing through molecular mechanisms mediated via the neurokinin-1 receptor. Diabetes. 2014;63(12):4262–4274. doi:10.2337/db14-0163.
  • Luo Y, Li P, Zhang C, et al. Effects of four antitussives on airway neurogenic inflammation in a guinea pig model of chronic cough induced by cigarette smoke exposure. Inflamm Res. 2013;62(12):1053–1061. doi:10.1007/s00011-013-0664-6.
  • Samarasinghe AE, Hoselton SA, Schuh JM. Spatio-temporal localization of vasoactive intestinal peptide and neutral endopeptidase in allergic murine lungs. Regul Pept. 2010;164(2-3):151–157. doi:10.1016/j.regpep.2010.05.017.
  • Larsson O, Tengroth L, Xu Y, Uddman R, Kumlien Georén S, Cardell L. Substance P represents a novel first-line defense mechanism in the nose. J Allergy Clin Immunol. 2018;141(1):128–136. doi:10.1016/j.jaci.2017.01.021.
  • Kowalska K, Carr DB, Lipkowski AW. Direct antimicrobial properties of substance P. Life Sci. 2002;71(7):747–750. doi:10.1016/s0024-3205(02)01740-x.
  • Stein RT, Bont LJ, Zar H, et al. Respiratory syncytial virus hospitalization and mortality: Systematic review and meta-analysis. Pediatr Pulmonol. 2017;52(4):556–569. doi:10.1002/ppul.23570.
  • Huang H, Deng L, Xiao F, et al. Clinical analysis of children with pertussis and significance of respiratory virus detection in the combined diagnosis. Zhonghua er ke za zhi [Chinese Journal of Pediatrics]. 2017;55(8):580. doi:10.3760/cma.j.issn.0578-1310.2017.08.007.
  • Sundaram ME, Meece JK, Sifakis F, Gasser RA, Belongia EA. Medically attended respiratory syncytial virus infections in adults aged ≥ 50 years: clinical characteristics and outcomes. Clin Infect Dis. 2014;58(3):342–349. doi:10.1093/cid/cit767.
  • Tripp RA, Moore D, Winter J, Anderson LJ. Respiratory syncytial virus infection and g and/or sh protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB/c mice. J Virol. 2000;74(4):1614–1622. doi:10.1128/JVI.74.4.1614-1622.2000.
  • Haynes LM, Jones LP, Barskey A, Anderson LJ, Tripp RA. Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to g glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J Virol. 2003;77(18):9831–9844. doi:10.1128/JVI.77.18.9831-9844.2003.
  • Haynes LM, Tonkin J, Anderson LJ, Tripp RA. Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection. J Virol. 2002;76(14):6873–6881. doi:10.1128/jvi.76.14.6873-6881.2002.
  • King KA, Hu C, Rodriguez MM, Romaguera R, Jiang X, Piedimonte G. Exaggerated neurogenic inflammation and substance P receptor upregulation in RSV-infected weanling rats. Am J Respir Cell Mol Biol. 2001;24(2):101–107. doi:10.1165/ajrcmb.24.2.4264.
  • Semple MG, Dankert HM, Ebrahimi B, et al. Severe respiratory syncytial virus bronchiolitis in infants is associated with reduced airway interferon gamma and substance P. PLoS One. 2007;2(10):e1038 doi:10.1371/journal.pone.0001038.
  • Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev. 2001;14(4):778–809. doi:10.1128/CMR.14.4.778-809.2001.
  • Di Domizio J, Blum A, Gallagher-Gambarelli M, Molens J, Chaperot L, Plumas J. TLR7 stimulation in human plasmacytoid dendritic cells leads to the induction of early IFN-inducible genes in the absence of type I IFN. Blood. 2009;114(9):1794–1802. doi:10.1182/blood-2009-04-216770.
  • Symes A, Lewis S, Corpus L, Rajan P, Hyman SE, Fink JS. STAT proteins participate in the regulation of the vasoactive intestinal peptide gene by the ciliary neurotrophic factor family of cytokines. Mol Endocrinol. 1994;8(12):1750–1763. doi:10.1210/mend.8.12.7708062.
  • Servidei T, Aoki Y, Lewis SE, Symes A, Fink JS, Reeves SA. Coordinate regulation of STAT signaling and c-fos expression by the tyrosine phosphatase SHP-2. J Biol Chem. 1998;273(11):6233–6241. doi:10.1074/jbc.273.11.6233.
  • Ramaswamy M, Shi L, Varga SM, Barik S, Behlke MA, Look DC. Respiratory syncytial virus nonstructural protein 2 specifically inhibits type I interferon signal transduction. Virology. 2006;344(2):328–339. doi:10.1016/j.virol.2005.09.009.
  • Lo MS, Brazas RM, Holtzman MJ. Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness. J Virol. 2005;79(14):9315–9319. doi:10.1128/JVI.79.14.9315-9319.2005.
  • Tripp RA, Dakhama A, Jones LP, Barskey A, Gelfand EW, Anderson LJ. The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P. J Virol. 2003;77(11):6580–6584. doi:10.1128/JVI.77.11.6580-6584.2003.
  • Li X, Fu ZF, Alvarez R, Henderson C, Tripp RA. Respiratory syncytial virus (RSV) Infects neuronal cells and processes that innervate the lung by a process involving RSV G protein. J Virol. 2006;80(1):537–540. doi:10.1128/JVI.80.1.537-540.2006.
  • Park Y, Lee J, Kwak J, et al. Fractalkine induces angiogenic potential in CX3CR1-expressing monocytes. J Leukoc Biol. 2018;103(1):53–66. doi:10.1189/jlb.1A0117-002RR.
  • Ho WZ, Lai JP, Zhu XH, Uvaydova M, Douglas SD. Human monocytes and macrophages express substance P and neurokinin-1 receptor. J Immunol. 1997;159(11):5654–5660.
  • Tang H, Inoue A, Iwasa M, Hide I, Nakata Y. Substance P release evoked by capsaicin or potassium from rat cultured dorsal root ganglion neurons is conversely modulated with bradykinin. J Neurochem. 2006;97(5):1412–1418. doi:10.1111/j.1471-4159.2006.03830.x.
  • Yasui K, Baba A, Iwasaki Y, et al. Neutrophil-mediated inflammation in respiratory syncytial viral bronchiolitis. Pediatr. Int. 2005;47(2):190–195. doi:10.1111/j.1442-200x.2005.02039.x.
  • Deng Y, Herbert JA, Smith CM, Smyth RL. An in vitro transepithelial migration assay to evaluate the role of neutrophils in respiratory syncytial virus (RSV) induced epithelial damage. Sci Rep. 2018;8(1):6777. doi:10.1038/s41598-018-25167-4.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.